GlassScriptPhysician profile
Manas Agastya
NPI 1629495759
$17,142.22
in general payments reported to CMS, 2019-2025
45 companies · $2,585 in 2025
The $2,585 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,500 · 2020: $169 · 2021: $14.13 · 2022: $305 · 2023: $2,111 · 2024: $10K · 2025: $2,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,245 · Consulting Fee: $4,625 · Food and Beverage: $2,788 · Education: $313 · Travel and Lodging: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,245.00 |
| Consulting Fee | $4,625.00 |
| Food and Beverage | $2,788.26 |
| Education | $312.66 |
| Travel and Lodging | $183.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $8,030.46 | 2019-2025 | Onivyde |
| Beigene USA, INC. | $2,043.44 | 2023-2025 | Brukinsa |
| Astrazeneca Pharmaceuticals LP | $2,029.37 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| Aveo Pharmaceuticals, INC. | $1,000.00 | 2023 | Fotivda |
| Astellas Pharma US INC | $502.67 | 2019 | |
| Abbvie INC. | $384.57 | 2019-2025 | Venclexta |
| Incyte Corporation | $230.63 | 2019-2023 | Monjuvi, Pemazyre |
| Amgen INC. | $211.08 | 2019 | |
| Pfizer INC. | $209.74 | 2019-2025 | |
| Janssen Biotech, INC. | $195.36 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Merck Sharp & Dohme LLC | $192.00 | 2019-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $155.58 | 2019-2024 | Fruzaqla |
| Seagen INC. | $149.58 | 2019-2023 | Padcev, Tukysa |
| Rigel Pharmaceuticals, INC. | $148.18 | 2019-2023 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $147.42 | 2022-2023 | Imbruvica, Epkinly |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $121.95 | 2023-2025 | |
| Eisai INC. | $117.61 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $117.42 | 2021-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $104.59 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $104.40 | 2022-2025 | Opdivo, Opdualag |
| Celgene Corporation | $96.08 | 2022-2024 | Pomalyst, Reblozyl |
| Genzyme Corporation | $82.20 | 2019-2024 | |
| Glaxosmithkline, LLC. | $78.15 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Stemline Therapeutics INC. | $77.24 | 2019-2025 | Orserdu |
| Emd Serono, INC. | $56.79 | 2023-2024 | Bavencio, Tepmetko |
| Lilly USA, LLC | $50.79 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Verastem, INC. | $48.88 | 2019-2020 | |
| Taiho Oncology, INC. | $42.11 | 2019 | |
| Mirati Therapeutics, INC. | $41.78 | 2023 | Krazati |
| Genentech USA, INC. | $38.98 | 2024 | Alecensa, Tecentriq, Rozlytrek |
| Daiichi Sankyo INC. | $36.72 | 2019-2024 | Enhertu |
| Genmab U.S., INC. | $32.39 | 2023 | Epkinly |
| Deciphera Pharmaceuticals INC. | $30.37 | 2023 | Qinlock |
| Janssen Pharmaceuticals, INC | $29.34 | 2019 | |
| Aimmune Therapeutics, INC. | $28.90 | 2025 | Zenpep |
| G1 Therapeutics, INC. | $24.58 | 2022 | |
| Aadi Bioscience, INC. | $23.26 | 2023 | Fyarro |
| Cti Biopharma Corp. | $23.21 | 2023 | Vonjo |
| Accord Healthcare, INC. | $21.14 | 2025 | |
| Jazz Pharmaceuticals INC. | $20.20 | 2020 | |
| Novocure INC. | $19.10 | 2025 | Optune Lua (Novottf-200t) |
| Aurobindo Pharma USA, INC. | $17.08 | 2019 | |
| Secura Bio, INC. | $15.01 | 2019 | |
| Dova Pharmaceuticals | $11.87 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manas Agastya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.